Alzheimer's Agent Fails; Antiseizure Drug Use Rises; Stress and Post-COVID Outcomes

(MedPage Today) -- Phase III studies of investigational gantenerumab did not meet their primary endpoints of slowing clinical decline in early Alzheimer's disease, the Roche Group said. Beta-amyloid removal also was lower than expected with the...

Source: MedPage Today Neurology - November 15, 2022 Category: Neurology Source Type: news